Evidence map›Paper›PMID 36452016›Full record

ReviewAsia Pacific allergy2022

Mechanisms and biomarkers of successful allergen-specific immunotherapy.

Juan-Felipe López, Manal Bel Imam, Pattraporn Satitsuksanoa, Sophieke Lems, Minglin Yang, Yu-Kyoung Hwang, Purevsuren Losol, Jun-Pyo Choi, Sae-Hoon Kim, Yoon-Seok Chang and 3 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Asia Pacific allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. A Pilot Randomised Controlled Dose-Ranging Trial of Ant Venom Immunotherapy With and Without Delta-Inulin Adjuvant.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Asia Pacific allergy · 2022
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Juan-Felipe LópezSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.ORCID https://orcid.org/0000-0002-9993-9530
Manal Bel ImamSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.ORCID https://orcid.org/0000-0002-7352-7204
Pattraporn SatitsuksanoaSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.ORCID https://orcid.org/0000-0001-9540-7759
Sophieke LemsSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
Minglin YangSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
Yu-Kyoung HwangDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.ORCID https://orcid.org/0000-0002-8025-7134
Purevsuren LosolDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.ORCID https://orcid.org/0000-0001-7620-1077
Jun-Pyo ChoiDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.ORCID https://orcid.org/0000-0001-8925-1786
Sae-Hoon KimDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.ORCID https://orcid.org/0000-0002-2572-5302
Yoon-Seok ChangDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.ORCID https://orcid.org/0000-0003-3157-0447
Mübeccel AkdisSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.ORCID https://orcid.org/0000-0003-0554-9943
Cezmi A AkdisSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.ORCID https://orcid.org/0000-0001-8020-019X
Willem van de VeenSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.ORCID https://orcid.org/0000-0001-9951-6688
University of Zurich · CHSeoul National University Bundang Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergen-specific immunotherapy (AIT) is considered the only curative treatment for allergic diseases mediated by immunoglobulin E (IgE). Currently, the route of administration depends both on the different types of causal allergens and on its effectiveness and safety profile. Several studies have reported the mechanisms and changes in humoral and cellular response underlying AIT; however, the full picture remains unknown. Knowledge of who can benefit from this type of treatment is urgently needed due to the patient safety risks and costs of AIT.

Indexed as

Allergen-specific immunotherapyAllergyBiomarkersIgEregulatory B cellsRegulatory T cells

Identifiers

PMID36452016
PMCPMC9669467
OpenAlexW4310600258

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.